Pharma Outsourcing – Find the Right Partner (2026)

Enabling 3D Multiplexing Spatial Omics Workflows in Neuroscience

Case study by ZEISS Microscopy.

Merck Life Science A/S

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Non-destructive testing and assembly control

Assess complete assembly.

Öresundsinstitutets vd: Novo Nordisk i aktiekris snarare än företagskris

Nedskärningarna på Novo Nordisk väcker frågor i hela den nordiska life science-sektorn. Men enligt Johan Wessman, vd för det dansk-svenska kunskapscentret Öresu...

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

Radioactive tracer to measure effect of drug towards Crohn’s disease

A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn's disease. That is the belief of Mari...

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Fast Optical Sectioning of Developing Organisms and Tissue Microstructures

ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Government apoints new experts to medicine and health council

Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Raised millions to develop a treatment for ´butterfly children´

Fragile as a butterfly’s wing – that’s how people living with Epidermolysis Bullosa are usually described. The Lund-based company Xinnate recently raised SEK 100 million in a new...

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.